8 main reasons for choosing intranasal corticosteroids in the treatment of allergic rhinitis
Article Sidebar
Published:
Jun 30, 2015
Keywords:
allergic rhinitis, rhinosinusitis, therapy, intranasal corticosteroids
Main Article Content
Abstract
Allergic rhinitis is the most common allergic disease in the population of Poland. Intranasal corticosteroids are currently the most effective anti-inflammatory drugs in the treatment of allergic rhinitis. Advantage of intranasal corticosteroids is their strong anti-inflammatory local action and little impact on general health. According to PoSLeNN and ARIA recommendations, intranasal corticosteroids are considered the first line drugs for moderate and severity intermittent and all stages of persistent allergic rhinitis.
Downloads
Download data is not yet available.
Article Details
How to Cite
Rapiejko , P. (2015). 8 main reasons for choosing intranasal corticosteroids in the treatment of allergic rhinitis. Alergoprofil, 11(2), 5-9. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/831
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Brożek J.L., Bousquet J., Baena-Cagnani C.E. et al.: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revison. J. Allergy Clin. Immunol. 2010; 126: 466-476.
2. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.
3. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013; S1.
4. Benninger M., Farrar J.R., Blaiss M. et al.: Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann. Allergy Asthma Immunol. 2010; 104: 13-29.
5. Greiner A.N., Hellings P.W., Rotiroti G. et al.: Allergic rhinitis. The Lancet 2012; 378(9809): 2112-2122.
6. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
7. Mygind N.: Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. BMJ 1973; 4: 464-466.
8. Alergiczny nieżyt nosa i jego wpływ na astmę. Raport ARIA 2001. Medycyna Praktyczna 2002; 07, wydanie specjalne: 1-263.
9. Arcimowicz M.: Glikokortykosteroidy donosowe u dzieci. Alergoprofil 2012; 8, 1: 5-17.
10. Bryson H.M., Faulds D.: Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 1992; 43: 760-775.
11. Teper A., Ratner P.H.: Mometasone furoate nasal spray is safe and effective for one-year treatment of children with perennial allergic rhinitis. J. Allergy Clin. Immunol. 2008; 121(suppl. 2): S52.
12. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – Not only in allergic rhinitis. Otolaryngol. Pol. 2014; 68(2): 51-64.
13. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014; 22, 10: 27-35.
14. Nayak A.S., Settipane G.A., Pedinoff A. et al.; Nasonex Sinusitis Group: Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Annals of Allergy, Asthma and Immunology 2002; 89: 271-278.
15. Zalmanovici A., Yaphe J.: Intranasal steroids for acute sinusitis. Cochrane Database Syst. Rev. 2009 Oct 7; (4): CD005149 [https://doi.org/10.1002/14651858.CD005149.pub3].
16. Ratajczak J., Rapiejko P., Wojdas A. et al.: Voice organ dysfunction in patients with allergic rhinitis sensitized to birch. Pol. J. Environ. Studies 2007; 16(1A): 51-54.
17. Ratajczak J., Rapiejko P., Wojdas A. et al.: Wpływ upośledzonej drożności nosa na jakość tworzonego głosu. Otolaryngol. Pol. 2009; 63(7): 58-63.
18. Samoliński B., Rapiejko P.: Odpowiedź późna po donosowej próbie prowokacyjnej z alergenem. Post. Dermatol. Alergol. 2010; 27(3): 173-176.
19. Daley-Yates P.T., Kunka R.I., Yin I. et al.: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004; 60: 265-268.
20. Allen D.B.: Systemic effects of intranasal steroids: An endocrinologist’s perspective. J. Allergy Clin. Immunol. 2000; 106: S179-190.
21. Schenkel E.J., Skoner P.D., Bronsky E.A. et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
22. Sastre J., Mosges R.: Local and systemic safety of intranasal corticosteroids. J. Investig. Allergol. Clin. Immunol. 2012; 22(1): 1-12.
23. Minshall E., Ghaffar O., Cameron L. et al.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648-654.
24. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33.
2. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.
3. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013; S1.
4. Benninger M., Farrar J.R., Blaiss M. et al.: Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann. Allergy Asthma Immunol. 2010; 104: 13-29.
5. Greiner A.N., Hellings P.W., Rotiroti G. et al.: Allergic rhinitis. The Lancet 2012; 378(9809): 2112-2122.
6. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
7. Mygind N.: Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. BMJ 1973; 4: 464-466.
8. Alergiczny nieżyt nosa i jego wpływ na astmę. Raport ARIA 2001. Medycyna Praktyczna 2002; 07, wydanie specjalne: 1-263.
9. Arcimowicz M.: Glikokortykosteroidy donosowe u dzieci. Alergoprofil 2012; 8, 1: 5-17.
10. Bryson H.M., Faulds D.: Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 1992; 43: 760-775.
11. Teper A., Ratner P.H.: Mometasone furoate nasal spray is safe and effective for one-year treatment of children with perennial allergic rhinitis. J. Allergy Clin. Immunol. 2008; 121(suppl. 2): S52.
12. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – Not only in allergic rhinitis. Otolaryngol. Pol. 2014; 68(2): 51-64.
13. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014; 22, 10: 27-35.
14. Nayak A.S., Settipane G.A., Pedinoff A. et al.; Nasonex Sinusitis Group: Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Annals of Allergy, Asthma and Immunology 2002; 89: 271-278.
15. Zalmanovici A., Yaphe J.: Intranasal steroids for acute sinusitis. Cochrane Database Syst. Rev. 2009 Oct 7; (4): CD005149 [https://doi.org/10.1002/14651858.CD005149.pub3].
16. Ratajczak J., Rapiejko P., Wojdas A. et al.: Voice organ dysfunction in patients with allergic rhinitis sensitized to birch. Pol. J. Environ. Studies 2007; 16(1A): 51-54.
17. Ratajczak J., Rapiejko P., Wojdas A. et al.: Wpływ upośledzonej drożności nosa na jakość tworzonego głosu. Otolaryngol. Pol. 2009; 63(7): 58-63.
18. Samoliński B., Rapiejko P.: Odpowiedź późna po donosowej próbie prowokacyjnej z alergenem. Post. Dermatol. Alergol. 2010; 27(3): 173-176.
19. Daley-Yates P.T., Kunka R.I., Yin I. et al.: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004; 60: 265-268.
20. Allen D.B.: Systemic effects of intranasal steroids: An endocrinologist’s perspective. J. Allergy Clin. Immunol. 2000; 106: S179-190.
21. Schenkel E.J., Skoner P.D., Bronsky E.A. et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
22. Sastre J., Mosges R.: Local and systemic safety of intranasal corticosteroids. J. Investig. Allergol. Clin. Immunol. 2012; 22(1): 1-12.
23. Minshall E., Ghaffar O., Cameron L. et al.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648-654.
24. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33.